Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541099 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT00541099 is a Phase 2 study of Lung Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 11 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00541099, a Phase 2 study of Lung Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, also work in different ways to kill tumor cells or stop them from growing. Giving bevacizumab together with docetaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel works in treating older patients with stage III or stage IV non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- BIOLOGICAL bevacizumab
Study Locations (3)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Nevada
- Nevada Cancer Institute - Las Vegas
Ohio
- Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00541099
The ClinicalTrials.gov registry entry for NCT00541099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00541099 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Nevada, Ohio.
Frequently Asked Questions
What is clinical trial NCT00541099 about?
NCT00541099 is a clinical study titled "Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by bloc...
What is the current status of trial NCT00541099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-01. Estimated completion is 2013-01.
What conditions does trial NCT00541099 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00541099?
The interventions under investigation include: docetaxel (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00541099?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00541099 being conducted?
This trial has 3 study locations across Michigan, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.